



(11) **EP 3 400 947 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.11.2018 Bulletin 2018/46

(51) Int Cl.:
A61K 31/7088 (2006.01) C12N 15/113 (2010.01)

(21) Application number: **18179911.5**

(22) Date of filing: **14.02.2014**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **VINEY, Nicholas J.**
Carlsbad, CA 92010 (US)
- **WITZTUM, Joseph L.**
San Diego, CA 92120 (US)

(30) Priority: **14.02.2013 US 201361764969 P**
20.09.2013 US 201361880779 P

(74) Representative: **Chapman, Desmond Mark**
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA (GB)

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
14751357.6 / 2 956 176

(71) Applicant: **Ionis Pharmaceuticals, Inc.**
Carlsbad, CA 92010 (US)

Remarks:

This application was filed on 26-06-2018 as a
divisional application to the application mentioned
under INID code 62.

(72) Inventors:
• **ALEXANDER, Veronica J.**
Carlsbad, CA 92010 (US)

(54) **MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE
DEFICIENT (LPLD) POPULATIONS**

(57) Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

EP 3 400 947 A1